Brian Park, PharmD

Drug Information Specialist https://www.dermatologyadvisor.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

Psoriasis

Amgen Looks to Expand Apremilast Plaque Psoriasis Indication

Brian Park, PharmD

March 4, 2021

Results showed that apremilast met the primary end point achieving a statistically significant improvement in sPGA response at week 16 compared with placebo.

Infections

Tick-Borne Encephalitis Vaccine Gets Priority Review

Brian Park, PharmD

March 4, 2021

TicoVac is an inactivated whole virus vaccine developed using a master ‘seed’ virus that is similar to the tick-borne encephalitis virus found in nature.

Practice Management

FDA: Certain Factors May Affect Pulse Oximeter Accuracy

Brian Park, PharmD

March 2, 2021

According to the FDA’s safety communication, multiple factors may affect the accuracy of pulse oximeter readings, including poor circulation, skin pigmentation, skin thickness, skin temperature, current tobacco use, and use of fingernail polish.

Dermatitis

Ruxolitinib Cream Under Review for Atopic Dermatitis

Brian Park, PharmD

February 26, 2021

The NDA submission also includes data from the 44-week, open-label, long term extension of both trials.

Investigational meningococcal vaccine may protect patients during outbreak

Practice Management

ACIP: 2021 Child and Adolescent Immunization Schedule Updates

Brian Park, PharmD

February 26, 2021

Fewer childhood vaccines have been administered due to a decline in outpatient pediatric visits resulting from the COVID-19 pandemic.

Practice Management

Fezolinetant Reduces Vasomotor Symptoms Associated With Menopause

Brian Park, PharmD

February 25, 2021

Fezolinetant is designed to reduce the frequency and severity of VMS associated with menopause by inhibiting neurokinin B binding on the kisspeptin/neurokinin/dynorphin neuron.

General Dermatology

Klisyri Ointment Now Available for Actinic Keratosis

Brian Park, PharmD

February 24, 2021

The approval was based on data from 2 multicenter, randomized, double-blind, phase 3 trials (ClinicalTrials.gov: NCT03285477 [N=351] and NCT03285490 [N=351]) that compared the efficacy and safety of Klisyri ointment to placebo in adults with AK on the face or scalp.

Dermatitis

Gusacitinib Fast Tracked for Chronic Hand Eczema

Brian Park, PharmD

February 11, 2021

The designation is supported by data from a randomized, double-blind, placebo-controlled phase 2b study that compared gusacitinib to placebo in 97 adult patients with moderate to severe chronic hand eczema.

Practice Management

AstraZeneca’s COVID-19 Vaccine Prevents Severe Disease, May Cut Transmission

Brian Park, PharmD

February 10, 2021

AZD1222 utilizes a replication-deficient chimpanzee adenovirus to deliver a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protein to induce a protective immune response.

Practice Management

No Added Benefit With Pembrolizumab Combo vs Monotherapy for Metastic NSCLC

Brian Park, PharmD

February 9, 2021

Results showed the median OS was 21.4 months in the pembrolizumab plus ipilimumab arm compared with 21.9 months in the pembrolizumab monotherapy arm.

Next post in Practice Management